Heat Biologics Provides Year-End 2021 Business Update
March 14, 2022 08:00 ET
|
Heat Biologics
DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...
Heat Biologics Announces Planned Transfer to the NYSE American
February 02, 2022 16:05 ET
|
Heat Biologics
DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
January 31, 2022 07:30 ET
|
Heat Biologics; Elusys Therapeutics, Inc.
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S....
Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110
January 12, 2022 08:00 ET
|
Heat Biologics
DURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Announces Planned Acquisition of Elusys Therapeutics
December 21, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats
November 30, 2021 07:30 ET
|
Heat Biologics
Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations Emergence of Omicron and other COVID-19 variants underscores the need for a...
Heat Biologics Provides Third Quarter 2021 Business Update
November 10, 2021 16:05 ET
|
Heat Biologics
DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), today provided strategic, financial, and operational updates for the third quarter ended September 30,...
Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy
October 06, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
September 15, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:30 ET
|
Heat Biologics
DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...